EP Patent

EP3498725A1 — 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy

Assigned to Sage Therapeutics Inc · Expires 2019-06-19 · 7y expired

What this patent protects

Provided herein is the compound:for use in the treatment of the following CNS-related conditions in a human subject: mood disorders (inlcuding depression), postnatal depression and positive and negative modulation of the GABAreceptor.

USPTO Abstract

Provided herein is the compound:for use in the treatment of the following CNS-related conditions in a human subject: mood disorders (inlcuding depression), postnatal depression and positive and negative modulation of the GABAreceptor.

Drugs covered by this patent

Patent Metadata

Patent number
EP3498725A1
Jurisdiction
EP
Classification
—
Expires
2019-06-19
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.